The executive team at Ginkgo Bioworks has a wide range of experience in the private equity, teaching, research, and biotechnology industries. Members of the team have attended Harvard Business School, Harvard University, the University of Illinois Urbana-Champaign, Northwestern University, the Massachusetts Institute of Technology, the University of Pennsylvania, and Yale University.
View all
23andMe
Post IPO Equity • Mountain View, United States
Twist Bioscience
Post IPO Equity • South San Francisco, United States
Adaptive Biotechnologies
Post IPO Equity • Seattle, United States
NanoString
Post IPO Equity • Seattle, United States
Standard BioTools
Post IPO Equity • South San Francisco, United States
Veracyte
Post IPO Equity • South San Francisco, United States
Insmed
Post IPO Equity • Bridgewater, United States
Sarepta Therapeutics
Post IPO Equity • Cambridge, United States
Sage Therapeutics
Post IPO Equity • Cambridge, United States
Aimmune Therapeutics
Post IPO Equity • Brisbane, United States
Atara Biotherapeutics
Post IPO Equity • South San Francisco, United States
Biohaven Pharmaceuticals
Post IPO Equity • New Haven, United States